Form D · Biotechnology
Braeburn Pharmaceuticals, Inc.
Princeton, NJ · CIK 0001688765
Offering snapshot reported Jan 19, 2018 · SEC filing
- Reported sold
- $110M Offering amount: $110M
- Investors reported
- 8 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 8, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 19, 2018 | Initial | $110,003,471 | No comparison | 8 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-303731
The aggregate offering amount and total amount sold have been rounded up to the next whole dollar.
Source: Form D, filed Jan 19, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jeffrey Berkowitz | Director |
| Michael Derkacz | Director, Executive |
| Seth L. Harrison, M.D. | Director, Executive |
| Argeris Karabelas, Ph.D. | Director |
| Patrick Kennedy | Director |
| Dennis H. Langer, J. D., M.D. | Director |
| Brian Markison | Director |
| David J. Mc Intyre | Executive |
| Asher M. Rubin | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
47 Hulfish Street Suite 441
Princeton, NJ, 08542
Princeton, NJ, 08542